Although AML is a cancer with a very low rate of somatic alterations, because of the constant identification of novel recurrent gene mutations, nowadays more than 90% of pediatric AML are identified to have at least one genomic alteration (10), among which those affecting FLT3 and KIT genes are very common in children, with more than 20% and 10% frequency, respectively, according to the TARGET study (7). This evidence concerns the gene FLT3 and acute myeloid leukemia.